|Videos|March 20, 2023
On the Horizon: Exciting Prospects in the Acute Lymphoblastic Leukemia Treatment Landscape
Closing thoughts from a panel of ALL experts on improving access to therapy and how their field may evolve in years to come.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
The FDA approved atezolizumab plus chemotherapy for the adjuvant treatment of stage III mismatch repair–deficient colon cancer.
The FDA granted fast track designation to the PSMA-targeted T-cell engager VIR-5500 for late-line metastatic castration-resistant prostate cancer.
MD Anderson Cancer Center announced the Texas Lone Star Cervical Cancer Elimination Plan 2027-2032, a 5-year roadmap to eliminate cervical cancer in Texas.
China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.
Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.
The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
2
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
3
VIR-5500 Receives FDA Fast Track Designation in mCRPC
4
September Roundup of FDA Approvals in Oncology: 8 Decisions to Know
5